#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.MedicalEntity|DCT|MedicalEntity
#T_RL=webanno.custom.TLINK|TLINK|BT_webanno.custom.MedicalEntity


#Text=20.03.2023:
#Text=Mann 68 år med KOLS GOLD 3 innkommer med økende dyspné siste 3 døgn.
1-1	0-10	20.03.2023	_	_	_	_	
1-2	10-11	:	_	_	_	_	
1-3	12-16	Mann	_	_	_	_	
1-4	17-19	68	_	_	_	_	
1-5	20-22	år	_	_	_	_	
1-6	23-26	med	_	_	_	_	
1-7	27-31	KOLS	BEFOREOVERLAP[1]	CONDITION[1]	_	_	
1-8	32-36	GOLD	BEFOREOVERLAP[1]	CONDITION[1]	_	_	
1-9	37-38	3	BEFOREOVERLAP[1]	CONDITION[1]	_	_	
1-10	39-48	innkommer	_	_	_	_	
1-11	49-52	med	_	_	_	_	
1-12	53-59	økende	OVERLAP[2]	CONDITION[2]	_	_	
1-13	60-66	dyspné	OVERLAP[2]	CONDITION[2]	_	_	
1-14	67-72	siste	_	_	_	_	
1-15	73-74	3	_	_	_	_	
1-16	75-79	døgn	_	_	_	_	
1-17	79-80	.	_	_	_	_	

#Text=SpO2 88% på romluft.
2-1	81-85	SpO2	_	_	_	_	
2-2	86-89	88%	_	_	_	_	
2-3	90-92	på	_	_	_	_	
2-4	93-100	romluft	_	_	_	_	
2-5	100-101	.	_	_	_	_	

#Text=Temperatur 38.2°C.
3-1	102-112	Temperatur	_	_	_	_	
3-2	113-117	38.2	_	_	_	_	
3-3	117-118	°	_	_	_	_	
3-4	118-119	C	_	_	_	_	
3-5	119-120	.	_	_	_	_	

#Text=Ekspiratoriske pipelyder bilateralt.
4-1	121-135	Ekspiratoriske	_	_	_	_	
4-2	136-145	pipelyder	_	_	_	_	
4-3	146-156	bilateralt	_	_	_	_	
4-4	156-157	.	_	_	_	_	

#Text=CRP 45.
5-1	158-161	CRP	_	_	_	_	
5-2	162-164	45	_	_	_	_	
5-3	164-165	.	_	_	_	_	

#Text=Starter Prednisolon 40mg x1 og Ery-Max 500mg x2.
6-1	166-173	Starter	_	_	_	_	
6-2	174-185	Prednisolon	AFTER[3]	TREATMENT[3]	_	_	
6-3	186-190	40mg	AFTER[3]	TREATMENT[3]	_	_	
6-4	191-193	x1	_	_	_	_	
6-5	194-196	og	_	_	_	_	
6-6	197-204	Ery-Max	AFTER[4]	TREATMENT[4]	OVERLAP	6-2[3_4]	
6-7	205-210	500mg	AFTER[4]	TREATMENT[4]	_	_	
6-8	211-213	x2	_	_	_	_	
6-9	213-214	.	_	_	_	_	

#Text=Intensiverer bronkodilaterende behandling.
7-1	215-227	Intensiverer	_	_	_	_	
7-2	228-245	bronkodilaterende	AFTER[5]	TREATMENT[5]	_	_	
7-3	246-256	behandling	AFTER[5]	TREATMENT[5]	_	_	
7-4	256-257	.	_	_	_	_	

#Text=Innlegges medisinsk avdeling for videre oppfølging.
8-1	258-267	Innlegges	AFTER[6]	TREATMENT[6]	OVERLAP	7-2[5_6]	
8-2	268-277	medisinsk	AFTER[6]	TREATMENT[6]	_	_	
8-3	278-286	avdeling	AFTER[6]	TREATMENT[6]	_	_	
8-4	287-290	for	_	_	_	_	
8-5	291-297	videre	_	_	_	_	
8-6	298-308	oppfølging	_	_	_	_	
8-7	308-309	.	_	_	_	_	
